Medicine information
Uses & overview
CABERGLOW 0.25 is a pharmaceutical formulation from Steris Healthcare containing Cabergoline IP 0.25 mg per tablet. Cabergoline is an ergot-derived dopamine D2 receptor agonist that acts on the pituitary gland to reduce the secretion of prolactin, a hormone involved in reproductive and lactation-related functions. Elevated prolactin levels, a condition known as hyperprolactinaemia, may be associated with irregular menstrual periods, unexpected milk production, reduced fertility, or other hormonal disturbances. Cabergoline may be prescribed after appropriate clinical assessment to help manage these conditions. Key Product Features Brand Name: CABERGLOW 0.25 Composition: Cabergoline IP 0.25 mg Company Name: Steris Healthcare Dosage Form: Tablet Therapeutic Category: Dopamine D2 receptor agonist Primary Use: Management of selected conditions associated with elevated prolactin levels Route of Administration: Oral, as directed by the approved product label Uses of CABERGLOW 0.25 Tablets Cabergoline is prescribed for certain conditions associated with excessive prolactin secretion, depending on the approved product information and local clinical guidelines. Potential clinical applications include: Hyperprolactinaemia: Helps lower abnormally elevated prolactin levels. Menstrual disturbances: May help address irregular or absent menstruation when these symptoms are associated with elevated prolactin. Reproductive health: May support the management of prolactin-related reproductive disturbances under specialist supervision. Prolactin-secreting pituitary tumours: May be prescribed as part of treatment for selected prolactinomas. The appropriate treatment depends on the cause of elevated prolactin, the patient's medical history, and the clinician's assessment. Not all menstrual irregularities or fertility concerns are caused by high prolactin levels. How Cabergoline Works Cabergoline stimulates dopamine D2 receptors in the pituitary gland. This action suppresses prolactin secretion, helping bring elevated prolactin levels towards the desired range. Depending on the underlying condition, treatment may help improve associated hormonal symptoms. Important Safety Information CABERGLOW 0.25 should be taken only as prescribed. Common side effects may include nausea, headache, dizziness, constipation, fatigue, and low blood pressure, particularly when standing up. Inform your healthcare professional if you have uncontrolled high blood pressure, heart valve disease, a history of fibrotic disorders, liver disease, or significant cardiovascular problems. Depending on the indication, treatment duration, and clinical history, your doctor may recommend blood pressure monitoring and other assessments. Cabergoline may cause dizziness or faintness, particularly when starting treatment or changing the dose. Avoid driving or operating machinery if you experience these effects. Discuss pregnancy and breastfeeding with your doctor before use, as recommendations depend on the indication and individual circumstances. Seek medical attention if you experience fainting, chest pain, breathing difficulties, persistent cough, or swelling of the legs. Do not change the dose or discontinue treatment without medical advice.
